Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Regenxbio Inc RGNX

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

NDAQ:RGNX - Post Discussion

Regenxbio Inc > REGENXBIO Announces Presentations at the American Academy of
View:
Post by whytestocks on Oct 18, 2024 1:45pm

REGENXBIO Announces Presentations at the American Academy of

Breaking News: $RGNX REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual MeetingREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting PR Newswire ROCKVILLE, Md. , Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal del...RGNX - REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities